Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma
- PMID: 15525739
- DOI: 10.1097/01.RVI.0000128123.04554.C1
Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma
Abstract
Purpose: To compare the value of the Child-Pugh and Model for End-stage Liver Disease (MELD) scores to predict patient survival rates after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
Materials and methods: Eighty-seven patients underwent 169 TACE sessions. Child-Pugh and MELD values were calculated before initial treatment. Survival length was tracked from the date of the first TACE procedure. Transplant recipients were censored from the study at the time of surgery. Child-Pugh and MELD scores as well as bilirubin and albumin levels and International Normalized Ratio were placed in high and low categories defined by their respective medians. Patient survival was compared at 3 months, 6 months, 12 months, and 24 months, and patterns were tested with chi2 or Fisher exact tests. Survival over the entire period was examined with Kaplan-Meier analysis and differences were tested with log-rank tests.
Results: Mean and median survival times for all patients were 24 and 17 months, respectively. Sixteen patients were censored for transplantation at a mean of 12.9 months. MELD and Child-Pugh scores correlated well with each other (r = 0.68). Child-Pugh score (r = -0.35, P = .04) correlated more strongly with 12-month survival than did MELD score (r = -0.26, P = .12). After high/low score category division, a significantly greater survival difference was predicted by Child-Pugh score (27.2 months vs 10.3 months; P = .03) versus MELD score (27.5 months vs 15.8 months; P = .19). An albumin level greater than 3.4 g/dL was also associated with significantly improved survival (29.3 months vs 10.1 months; P = .0032). Survival differences between high-risk and low-risk groups at the 3-, 6-, 12-, and 24-month intervals were significant for low Child-Pugh scores and for albumin levels greater than 3.4 g/dL. Statistical significance was not approached at any of the time lengths with MELD scores.
Conclusions: Child-Pugh score correlates better than MELD score to overall patient survival and is a better predictor than MELD score of survival at specific time points. Of the components of the Child-Pugh and MELD systems, albumin level is the most useful predictor of survival.
Similar articles
-
Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.Scand J Gastroenterol. 2009;44(3):346-57. doi: 10.1080/00365520802530838. Scand J Gastroenterol. 2009. PMID: 18991165
-
Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.Hepatogastroenterology. 2003 Jan-Feb;50(49):207-12. Hepatogastroenterology. 2003. PMID: 12630024 Clinical Trial.
-
Chemoembolization in patients at high risk: results and complications.J Vasc Interv Radiol. 2006 Jan;17(1):47-53. doi: 10.1097/01.RVI.0000195074.43474.2F. J Vasc Interv Radiol. 2006. PMID: 16415132
-
Chemoembolization of hepatocellular carcinoma--what to tell the skeptics: review and meta-analysis.Tech Vasc Interv Radiol. 2002 Sep;5(3):122-6. doi: 10.1053/tvir.2002.36418. Tech Vasc Interv Radiol. 2002. PMID: 12524642 Review.
-
Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.J Vasc Interv Radiol. 2014 Jul;25(7):1075-84. doi: 10.1016/j.jvir.2014.04.014. Epub 2014 May 24. J Vasc Interv Radiol. 2014. PMID: 24861664 Review.
Cited by
-
Multivariate analysis of prognostic factors for survival following doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.J Vasc Interv Radiol. 2013 May;24(5):647-54. doi: 10.1016/j.jvir.2012.12.003. Epub 2013 Feb 4. J Vasc Interv Radiol. 2013. PMID: 23384831 Free PMC article.
-
Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study.Anticancer Agents Med Chem. 2024;24(17):1241-1252. doi: 10.2174/0118715206313132240712101607. Anticancer Agents Med Chem. 2024. PMID: 39034727
-
Comparison of chemoembolization with CalliSpheres® microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study.Cancer Manag Res. 2020 Feb 10;12:941-956. doi: 10.2147/CMAR.S187203. eCollection 2020. Cancer Manag Res. 2020. PMID: 32104076 Free PMC article.
-
Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma.J Cancer Res Clin Oncol. 2020 Apr;146(4):1033-1050. doi: 10.1007/s00432-020-03135-8. Epub 2020 Feb 27. J Cancer Res Clin Oncol. 2020. PMID: 32107625 Free PMC article.
-
Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma.World J Gastroenterol. 2014 Dec 7;20(45):17132-40. doi: 10.3748/wjg.v20.i45.17132. World J Gastroenterol. 2014. PMID: 25493027 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous